ArticleFrontiers in cardiovascular medicine2025
Global burden and health inequality of atrial fibrillation/atrial flutter from 1990 to 2021.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Direct oral anticoagulants versus vitamin K antagonists after left atrial appendage occlusion: a systematic review and meta-analysis.BMC cardiovascular disorders · 2026Pooled it
- Sex-based disparities in postoperative outcomes after catheter ablation for atrial fibrillation: a systematic review and meta-analysis of propensity-matched studies.BMC cardiovascular disorders · 2026Pooled it
- Epidemiologic shift and future projections of atrial fibrillation and flutter in North Africa and the Middle East region: A comprehensive Global Burden of Disease analysis.Heart rhythm O2 · 2026Article
- Targeted Quantitative Metabolomics and Lipidomics Reveal Dysregulated Metabolic Networks and a Serum Candidate Biomarker for Atrial Fibrillation.Metabolites · 2026Article
- Predictors and Outcomes of 30-Day Readmissions Following Electrical Cardioversion for Atrial Fibrillation: Insights From the Nationwide Readmissions Database.Journal of arrhythmia · 2026Article
- Modifiable Risk Factors for Atrial Fibrillation/Flutter in the Association of Southeast Asian Nations: Global Burden of Disease 2021.JACC. Advances · 2026Article
- Same day discharge can be performed safely after atrial fibrillation catheter ablation using a wide-footprint lattice-tip dual-energy system.Heart rhythm O2 · 2026Article
- Reimagining atrial fibrillation screening beyond age-based thresholds using AI.NPJ digital medicine · 2026Article
- Phenotypic age acceleration and omega-6/omega-3 PUFA ratio in dynamic atrial fibrillation-heart failure transitions: a multistate analysis.The journal of nutrition, health & aging · 2026Article
- Article
- Versatile hiPSC Models and Bioengineering Platforms for Investigation of Atrial Fibrosis and Fibrillation.Cells · 2026Review
- Exploring nurse- and allied health professional-led opportunistic atrial fibrillation screening with artificial intelligence-enabled devices in community and primary care.Frontiers in cardiovascular medicine · 2026Review
- Next-Generation Anticoagulants: Precision Strategies for Patient-Centered Thromboprophylaxis.Journal of personalized medicine · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atrial fibrillation (AF) and atrial flutter (AFL) are the most prevalent tachyarrhythmias worldwide, leading to severe complications such as stroke and heart failure. Despite advancements in diagnosis and management, the global burden of AF/AFL continues to increase, highlighting the urgent need for comprehensive epidemiological research. Methods: This study analyzed data from the Global Burden of Disease (GBD) 2021 to examine the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) associated with AF/AFL from 1990 to 2021. Age-standardized rates were calculated at global, regional, and country-specific levels. Decomposition and Bayesian age-period-cohort models were used to explore trends and forecast future disease burdens. Results: In 2021, AF/AFL contributed to 4.48 million new cases globally, with an age-standardized incidence rate (ASIR) of 52.1 per 100,000. The global prevalence reached 52.55 million cases, while the disease caused 338,947 deaths. The global age-standardized DALY rate stood at 101.4 per 100,000. Significant disparities were observed, with higher disease burdens in high Socio-demographic Index (SDI) regions compared to low SDI regions. Between 1990 and 2021, aging and population growth were key drivers of the increased burden, with regional variations associated with economic development and healthcare access. Bayesian projections indicate a gradual rise in incidence and prevalence through 2050, although mortality and DALY rates are expected to decline. Conclusions: AF/AFL presents a substantial public health challenge, with rising incidence and prevalence primarily driven by demographic changes and enhanced diagnostic capabilities. Addressing health inequalities requires targeted interventions and strengthening healthcare systems. Future strategies should prioritize prevention and equitable access to advanced therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.